Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- EPS: Sales Up, Profits Down due to Slump of CRO Business
August 15, 2011
- JPO's WG to Resume Discussions to Revise Patent Term Extension Rule for DDS Preparations
August 15, 2011
- Asahi Kasei to Make Asahi Kasei Kuraray Medical a Wholly-owned Subsidiary
August 15, 2011
- Qol Opens Dispensing Pharmacy at Major Electronics Retail Store
August 15, 2011
- Nichi-Iko to Strengthen Relationships with Wholesalers
August 15, 2011
- NCVC to Expand Infrastructure for 1st-in-human Studies for Medical Devices
August 15, 2011
- FIRM Starts Activities Creating 3 WGs
August 15, 2011
- Daiichi Sankyo to Expand Hybrid Business Model in Mexico
August 15, 2011
- Combination Drugs Are Part of Innovation: Prof. Kaku of Kawasaki Medical School
August 15, 2011
- Statistics
August 15, 2011
- DSP Not Planning Full-scale Entry into Generic Business: President Tada
August 15, 2011
- Korosho Forecasts 92,000 Patients Admitted for Dementia in 2026
August 15, 2011
- Korosho's Study Group Proposes Qualifications for GMP Inspectors
August 15, 2011
- Fuji Pharma: Sales Up 7% Driven by Hormonal Drugs
August 15, 2011
- M3 Survey of Doctors Finds Differences in Ways Companies Detail AD Treatments
August 15, 2011
- Fee-for-Service Reimbursement to Be Permitted for Wider Range of High-priced Drugs
August 15, 2011
- SRUVEY
August 15, 2011
- Korosho Orders 10-Day Suspension of Operations for Kobayashi Medical
August 8, 2011
- M3 to Promote Clinical Study Support Business by Acquiring SMO
August 8, 2011
- Roche to File for mBC Treatment Pertuzumab in Japan in 2012
August 8, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…